A new Works in Progress article argues that the U.S. has spent roughly 15 years trapping mosquito-control biotechnology in a regulatory system that was not built for it, even though methods for sharply reducing disease-carrying mosquito populations already exist.
The piece, by Maya Rosen, centers on two approaches: genetically engineered mosquitoes from Oxitec and Wolbachia-based mosquito control from MosquitoMate. In both cases, the article argues, the main obstacle has not simply been whether the technologies can work, but how older regulatory categories have handled products that do not fit neatly into them.
Oxitec’s long path through three agencies
Rosen writes that Oxitec engineered male Aedes aegypti mosquitoes so that female offspring die before adulthood, while male offspring survive for a few generations before the trait fades out. That species is a known vector for diseases including dengue and yellow fever.
The article says sustained releases produced large reductions in wild mosquito populations: 80 percent in the Cayman Islands and about 95 percent in a field trial in Juazeiro, Brazil.
Oxitec then sought U.S. approval in 2010. Rosen writes that the company first applied to the USDA, which took about a year and a half to reject the application and redirect it to the FDA. The FDA, in turn, kept the application for another five years before concluding that the EPA was the better fit, because the mosquitoes were being used for population control.
That left Oxitec under pesticide rules at the EPA. Rosen writes that the agency granted the company an Experimental Use Permit in May 2020, allowing field trials but not full commercial sale or routine deployment. In 2022, the EPA expanded those trials to California, clearing releases in California and Florida, though the article says the California releases were paused after public pushback.
The permit expired in April 2024, the article says, which meant no further releases could proceed without new EPA authorization. Full commercial registration remains pending.
MosquitoMate finally reached nationwide registration
The article also highlights MosquitoMate, whose approach relies on Wolbachia, a bacterium that can suppress mosquito populations when infected males mate with uninfected females and produce eggs that do not develop.
Rosen writes that MosquitoMate became the first company to receive full nationwide commercial registration for a live mosquito biopesticide in April 2024, after 15 years in the regulatory system. The article says mosquito control districts moved quickly to use the technology, including in the Florida Keys in 2025 and the San Gabriel Valley in 2026.
The broader argument
Rosen’s broader claim is that the hold-up reflects regulatory design as much as scientific review. The article says the federal framework still rests on a structure created in 1986 and divides oversight using categories built for older kinds of products. In that telling, mosquito-control biotech has been slowed not only by safety and efficacy review, but by repeated fights over which agency should oversee it at all.
